Literature DB >> 9766519

Angiotensin II-stimulated collagen gel contraction by heart fibroblasts: role of the AT1 receptor and tyrosine kinase activity.

S Watson1, T Burnside, W Carver.   

Abstract

The accumulation and organization of extracellular matrix (ECM) components play critical roles in development, maintenance, and pathogenesis of most organ systems. These processes are regulated by the precisely orchestrated expression of ECM components, their receptors, and matrix proteases. The collagen gel culture system has been extensively used as a model to examine ECM remodeling similar to that which occurs during development and wound healing. Growth factors, including transforming growth factor-beta, platelet-derived growth factor, insulin-like growth factor, and angiotensin II, have been shown to stimulate collagen gel contraction. The present studies were undertaken to begin to examine the mechanisms through which angiotensin II stimulates collagen remodeling and gel contraction. These studies indicate that angiotensin II stimulates collagen gel contraction by isolated heart fibroblasts in a dose-dependent manner and that this response is inhibited by the AT1 receptor antagonist Losartan. Furthermore, stimulation of collagen gel contraction by angiotensin II is also blocked by the src-related tyrosine kinase inhibitors genistein and herbimycin, indicating that activation of tyrosine kinases plays critical roles in this process. Stimulation of gel contraction by angiotensin II also involves the activation of JAK2, a member of the JAK/STAT pathways of transcriptional activation. Immunoprecipitation of surface-labeled fibroblasts indicate that cell surface levels of collagen-binding integrins also increase in response to angiotensin II treatment. Determining the underlying mechanisms regulating ECM remodeling is essential to understanding the role of ECM organization in development and disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9766519     DOI: 10.1002/(SICI)1097-4652(199811)177:2<224::AID-JCP4>3.0.CO;2-P

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

1.  Effects of elevated glucose levels on interactions of cardiac fibroblasts with the extracellular matrix.

Authors:  Xiaoyi Zhang; James A Stewart; Ian D Kane; Erin P Massey; Dawn O Cashatt; Wayne E Carver
Journal:  In Vitro Cell Dev Biol Anim       Date:  2007-09-12       Impact factor: 2.416

2.  Targeting the renin-angiotensin-aldosterone system in fibrosis.

Authors:  Mohammad AlQudah; Taben M Hale; Michael P Czubryt
Journal:  Matrix Biol       Date:  2020-05-16       Impact factor: 11.583

Review 3.  Molecular mechanisms of AGE/RAGE-mediated fibrosis in the diabetic heart.

Authors:  Jia Zhao; Rushil Randive; James A Stewart
Journal:  World J Diabetes       Date:  2014-12-15

4.  Altered expression of angiotensin II receptor subtypes and transforming growth factor-beta in the heart of nitrofen-induced diaphragmatic hernia in rats.

Authors:  Honami Teramoto; Masato Shinkai; Prem Puri
Journal:  Pediatr Surg Int       Date:  2004-12-02       Impact factor: 1.827

5.  Contractility of placental vascular smooth muscle cells in response to stimuli produced by the placenta: roles of ACE vs. non-ACE and AT1 vs. AT2 in placental vessel cells.

Authors:  C Benoit; Y Gu; Y Zhang; J S Alexander; Y Wang
Journal:  Placenta       Date:  2008-04-15       Impact factor: 3.481

6.  Cardiac fibroblast-dependent extracellular matrix accumulation is associated with diastolic stiffness in type 2 diabetes.

Authors:  Kirk R Hutchinson; C Kevin Lord; T Aaron West; James A Stewart
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

7.  Pleiotropic Effects of Simvastatin and Losartan in Preclinical Models of Post-Traumatic Elbow Contracture.

Authors:  Michael A David; Alex J Reiter; Chelsey L Dunham; Ryan M Castile; James A Abraham; Leanne E Iannucci; Ishani D Shah; Necat Havlioglu; Aaron M Chamberlain; Spencer P Lake
Journal:  Front Bioeng Biotechnol       Date:  2022-02-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.